Navigation Links
Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto l'endpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
Date:9/17/2013

e del glucosio nei pazienti diabete ad elevato rischio di patologie cardiovascolari," ha dichiarato William B. White, MD, FASH, FAHA, FACP, ricercatore principale dello studio EXAMINE. "Considerato il concetto su cui è stato costruito lo studio EXAMINE e la popolazione a elevato rischio valutata, questi risultati forniscono importanti informazioni ai medici che curano pazienti diabetici affetti da malattia coronarica."

Lo studio globale EXAMINE costituisce una valutazione importante poiché prende in esame la sicurezza cardiovascolare in pazienti di cui è noto l'elevato rischio di malattie cardiovascolari (CVD), causa principale di condizioni patologiche e mortalità nella popolazione di pazienti affetti da diabete di tipo 2. EXAMINE, uno studio clinico globale, di grandi dimensioni, randomizzato, in doppio cieco, controllato verso placebo, è stato concepito per valutare la sicurezza cardiovascolare del trattamento con alogliptin in aggiunta alla terapia standard, rispetto al placebo in aggiunta alla sola terapia standard, in pazienti affetti da diabete di tipo 2 e con un ACS (sindrome coronarica acuta) recente.

Nel corso dello studio EXAMINE, i pazienti sono stati assegnati a random al gruppo che sarebbe stato trattato con alogliptin o a quello che sarebbe stato trattato con placebo in aggiunta ai medicinali normalmente previsti per il trattamento del diabete e delle malattie cardiovascolari. 5.380 pazienti sono stati assegnati a random e sono stati seguiti per un tempo mediano di 18 mesi e per un tempo massimo di 40 mesi. Il tasso di interruzioni anticipate del trattamento in studio è stato simile nel gruppo trattato con alogliptin e in quello trattato con il placebo. I pazienti sono stati curati secondo livelli elevati di standard terapeutico del diabete di tipo 2 e dei fattori di rischio cardiovascolari.

"Il disegno dello studio EXAMINE e soprattutto i risultati rilevati per la sicure
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anthony Creed Joins DDSTUDIO As GM, Experience Design
2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
4. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
5. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
6. River City Laser Tattoo Removal Studio Offers Grand Opening Discounts on Treatments Using the Astanza Revolution Laser
7. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
8. New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments
9. Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
10. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
11. The Food Journal Examines Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... ("CompCare") (OTC BB: CHCR), a leading behavioral health, substance ... care companies throughout the U.S., today announced that its ... 31, 2012 totaled $17,890,000.  Net income totaled $80,000 for ... announce that CompCare achieved a profit, albeit modest, for ...
... SUNNYVALE, Calif. and BELGRADE, Serbia, May 22, 2012 ... cardiovascular and renal diseases, presented positive data from its ... of 111 heart failure patients with chronic kidney disease, ... to placebo.    Data from the randomized, ...
Cached Medicine Technology:Comprehensive Care Corporation Announces Profit for First Quarter 2Comprehensive Care Corporation Announces Profit for First Quarter 3Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3
(Date:12/19/2014)... December 19, 2014 If you have ... difficulty breathing, you probably wished you had an arsenal ... COPD, cystic fibrosis, and other breathing disorders. Currently, the ... and avoiding triggers, but other common treatments do exist. ... conference in San Antonio, TX, 34 asthma educators responded ...
(Date:12/19/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Gliquidone manufacturers and is a valuable source of ... the industry. , Firstly, the report provides a basic ... manufacturing technology. Then, the report explores the international and ...
(Date:12/19/2014)... A new study suggests a possible link between certain ... night sweats -- and higher rates of hip fractures ... menopause, affecting about 60 percent of women. The hormonal ... they then face a higher risk of weakened bones ... moderate or severe menopausal symptoms are more likely to ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
Breaking Medicine News(10 mins):Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... Ind., Jan. 20 Conseco, Inc. (NYSE: ... a stockholder rights plan,designed to protect stockholder value by ... tax net operating loss carryforwards under,Section 382 of the ... value,of those tax assets upon an "ownership change." ...
... purchased raw milk from the Conestoga Valley Dairy Farm ... to the risk of Salmonella contamination, Agriculture Secretary Dennis ... to kill disease-causing bacteria or homogenized. Pennsylvania farms selling ... samples tested in a laboratory due to the health ...
... Foundation to Host Five Cancer Fighters on January 30th ... Jan. 20 Lillians(TM), The Hippest Shoppe in Town(R) ... announced that it will postpone "the dance," its annual ... until Friday, Oct. 23, 2009, at the Medina Entertainment ...
... enterprise WLAN solution for point-of-care, voice and AeroScout asset ... Inc. (NYSE: MOT ) today announced ... LAN (WLAN) solution to support several of its current ... a 680-bed facility providing quality patient care in Montreal, ...
... other chemicals boost their odds of respiratory trouble, ... -- Frequent exposure to hospital cleaning products and ... to a U.S. study that included 3,650 Texan ... researchers found that nurses regularly exposed to cleaning ...
... MassMutual,s Retirement Services Division has added three new ... third-party administrators (TPA). The new TPA relationship managers ... investment change processing, product and service education and ... platform. Karen Buoniconti joined MassMutual,s TPA ...
Cached Medicine News:Health News:Conseco Adopts Stockholder Rights Plan 2Health News:Conseco Adopts Stockholder Rights Plan 3Health News:Conseco Adopts Stockholder Rights Plan 4Health News:Conseco Adopts Stockholder Rights Plan 5Health News:Lillians(TM) Postpones 'The Dance' Fundraising Event; New Date Is October 23, 2009 2Health News:Montreal Jewish General Hospital Improves Care and Reduces Costs With Motorola's Enterprise Mobility Solution 2Health News:Montreal Jewish General Hospital Improves Care and Reduces Costs With Motorola's Enterprise Mobility Solution 3Health News:Cleaning Products Up Nurses' Asthma Risk 2Health News:MassMutual Retirement Services Appoints Three New TPA Relationship Managers 2
All Bovie LLETZ Loop and Square electrodes feature tungsten wire for superior shape and integrity throughout the excision procedure. They use a standard 3/32" (2.3 mm) shaft....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
Disposable 1 1/4" Tungsten Micro Needle, Ins., Straight...
Split adult return electrode grounding pad with 2.8 m cable, 50/box....
Medicine Products: